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Chronic feeding on high-calorie diets causes obesity
and type 2 diabetes mellitus (T2DM), illnesses that
affect hundreds of millions. Thus, understanding
the pathways protecting against diet-induced meta-
bolic imbalance is of paramountmedical importance.
Here, we show that mice lacking SIRT1 in steroido-
genic factor 1 (SF1) neurons are hypersensitive to
dietary obesity owing to maladaptive energy expen-
diture. Also, mutant mice have increased suscepti-
bility to developing dietary T2DM due to insulin resis-
tance in skeletal muscle. Mechanistically, these
aberrations arise, in part, from impaired metabolic
actions of the neuropeptide orexin-A and the
hormone leptin. Conversely, mice overexpressing
SIRT1 in SF1 neurons are more resistant to diet-
induced obesity and insulin resistance due to
increased energy expenditure and enhanced skeletal
muscle insulin sensitivity. Our results unveil impor-
tant protective roles of SIRT1 in SF1 neurons against
dietary metabolic imbalance.
INTRODUCTION
Feeding on high-calorie (HC) diets and following sedentary life-
styles are thought to play critical pathogenic roles in the develop-
ment of obesity and type 2 diabetes mellitus (T2DM) (Vianna and
Coppari, 2011; Wisse et al., 2007). Chronic hypercaloric feeding
causes energy and glucose/insulin imbalance in mammalian
organisms, including nonhuman primates (McCurdy et al.,
2009; Surwit et al., 1988), thus supporting a cause-effect rela-
tionship between HC diets and metabolic diseases. Because
some subjects are more resistant than others to developing
diet-induced metabolic dysfunctions (Enriori et al., 2007),
heterogeneities in the robustness of homeostatic mechanisms
against dietary obesity and T2DM must exist. The behavioral
and autonomic adaptations against dietary obesity are partially
understood; these include reduced food intake and increased
energy expenditure, respectively (Dhillon et al., 2006; Ramadori
et al., 2010; Tong et al., 2008). On the other hand, the protectiveCell Memechanism(s) against dietary T2DM is unknown. Considering
that hundreds of millions of people are affected by obesity
and/or T2DM (both of which greatly increase the risk of cardio-
vascular disease and cancer), a better understanding of the
key molecules and cell types that coordinate homeostatic
responses against increased body adiposity and glucose/insulin
imbalance is of paramount scientific and medical importance.
Neurons within the hypothalamus detect changes in circu-
lating amounts of hormones and substrates and relay this infor-
mation into adaptive outputs aimed at maintaining normal
energy and glucose/insulin homeostasis (Coppari et al., 2005;
Hill et al., 2010; Lam et al., 2005; Parton et al., 2007; Pocai
et al., 2005; Ramadori et al., 2010; Vianna and Coppari, 2011).
Among these cells, neurons within the ventromedial hypotha-
lamic nucleus (VMH) have been shown to be of particular impor-
tance. Indeed, loss of leptin receptor (LEPR) in steroidogenic
factor 1 (SF1)-expressing neurons (a group of cells found only
in the VMH within the brain [Ikeda et al., 1993; Luo et al.,
1994]) significantly predisposes to developing obesity (Dhillon
et al., 2006). Similarly, reduced phosphoinositide 3-kinase
(PI3K) signaling in SF1 neurons (induced by SF1-neuron-specific
deletion of p110a, a catalytic subunit of PI3K) impairs autonomic
responses to hypercaloric feeding and consequentially engen-
ders hypersensitivity to diet-induced obesity (Xu et al., 2010).
VMH neurons are also thought to govern glucose/insulin
homeostasis because: (i) the VMH is enriched in glucose-
sensing neurons (Oomura et al., 1964); (ii) VMH-centered electri-
cal stimulation or leptin administration stimulates glucose uptake
in peripheral tissues (Minokoshi et al., 1999; Sudo et al., 1991);
(iii) SF1-neuron-specific deletion of LEPR causes insulin resis-
tance (Bingham et al., 2008); (iv) enhanced LEPR signaling
in SF1 neurons (induced by SF1-neuron-specific deletion of
suppressor of cytokine signaling 3, a negative regulator of
LEPR signaling) augments insulin sensitivity (Zhang et al.,
2008); and (v) the actions of orexins (also known as hypocretins;
two neuropeptides, orexin-A and orexin-B, secreted from
neurons within the lateral hypothalamic area [LHA]) on VMH
neurons have been linked to increased insulin sensitivity in skel-
etal muscle (Shiuchi et al., 2009). Interestingly, VMH neurons
project excitatory synapses to hypothalamic arcuate nucleus
(ARH) pro-opiomelanocortin (POMC) neurons (Sternson et al.,
2005), a group of neurons that has been shown to coordinate
defensive mechanisms against diet-induced obesity (Ramadoritabolism 14, 301–312, September 7, 2011 ª2011 Elsevier Inc. 301
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et al., 2007). Together, these findings suggest that VMH SF1
neurons are important rheostats of metabolic function that, by
sensing changes in extracellular amounts of metabolic cues
(e.g., leptin, orexin, glucose), coordinate homeostatic responses
aimed at maintaining normal body weight and glucose/insulin
homeostasis.
SIRT1 is a metabolic-sensor protein that requires oxidized
nicotinamide adenine dinucleotide (NAD+) as a cofactor for its
enzymatic activity (Imai et al., 2000). SIRT1 deacetylates diverse
proteins (e.g., histones, transcription factors, and cofactors) and
therefore influences several biological programs (Ramadori and
Coppari, 2010). An emerging and converging view is that SIRT1
(the orthologs of which are found in several species) has been
conserved throughout evolution due to its robust protective
actions (Haigis and Sinclair, 2010). For example, SIRT1 is crucial
for appropriate adaptations to fasting. Indeed, SIRT1 activity
increases in several tissues (including the hypothalamus)
following a decrease in energy availability (Cohen et al., 2004;
Ramadori et al., 2008). In this context, SIRT1 triggers lipid mobi-
lization from adipose tissue (Picard et al., 2004), a switch from
glucose to lipid oxidation in skeletal muscle (Gerhart-Hines
et al., 2007) and liver (Purushotham et al., 2009), and an increase
in hepatic glucose production (Rodgers et al., 2005), all of which
are crucial defense mechanisms against diminished energy
availability. SIRT1 has also been shown to exert protective
actions against Alzheimer’s disease, amyotrophic lateral scle-
rosis (Donmez et al., 2010; Kim et al., 2007a; Qin et al., 2006),
and axonal degeneration (Araki et al., 2004). In addition, we
have recently reported that SIRT1 in POMC neurons is a critical
molecular component of autonomic mechanisms against dietary
obesity (Ramadori et al., 2010).
SIRT1 is abundantly expressed in VMH (Ramadori et al., 2008).
Thus, we hypothesized that SIRT1 in neurons within this hypo-
thalamic structure is a key molecular component of protective
pathways against excessive body weight gain and glucose/
insulin imbalance. In this study, we directly tested this hypoth-
esis by investigating the metabolic consequences of either loss
or overexpression of SIRT1 only in SF1 neurons in mice.
RESULTS
Somatic Deletion of SIRT1 in SF1 Neurons
Cre-mediated deletion of the loxP-flanked exon 4 of Sirt1
(Sirt1loxP) produces a Sirt1 null allele (Cheng et al., 2003). Thus,
to generate mice lacking SIRT1 in SF1 neurons, the Sirt1loxP
allele was bred to the Sf1-Cre transgene that expresses func-
tional Cre-recombinase only in SF1 cells (Dhillon et al., 2006;
Tong et al., 2007; Xu et al., 2010). To determine if Sf1-Cre mice
homozygous for the Sirt1loxP allele (hereafter referred to as Sf1-
Cre; Sirt1loxP/loxP mice) lack SIRT1 only in SF1 cells, we first
carried out genotyping PCR analysis of several tissues. The
Cre-deleted Sirt1 allele was detected only in the hypothalamus,
pituitary, testis, ovary, and adrenal gland of Sf1-Cre; Sirt1loxP/loxP
mice (Figure S1A). SIRT1 deletion in these sites is expected, as
SF1 is expressed only in the VMH, pituitary (gonadotropes),
testis (Leydig cells), ovaries (corpus luteum and theca and gran-
ulosa cells), and adrenal cortex (Ikeda et al., 1993; Luo et al.,
1994). SIRT1 deletion in SF1-expressing peripheral tissues was302 Cell Metabolism 14, 301–312, September 7, 2011 ª2011 Elsevieinconsequential, as fertility capacity (i.e., the average age of first
delivery, litter size, time between deliveries), estrous cycle,
gonadal weight, and serum testosterone levels were all undistin-
guishable between mutants and controls (Table S1 and data not
shown). Also, the basal circadian fluctuations and stress-
induced levels of serum corticosterone were normal in mutants
(Table S1).
To further investigate SIRT1 deletion in the central nervous
system (CNS), the amount of full-length Sirt1 mRNA was
measured and found to be reduced in hypothalamus of Sf1-
Cre; Sirt1loxP/loxP mice (Figure S1B). These data suggest that
SIRT1 is absent only in SF1 neurons. To directly test this possi-
bility, immunohistochemistry (IHC) analyses of brains from
Sirt1loxP/loxP (control) and mutant mice were performed using
SIRT1-specific antibodies (Ramadori et al., 2010). In line with
our previous results (Ramadori et al., 2008), numerous SIRT1-
positive cells were detected in the VMH of controls (Figure S1C,
upper panel). It is noteworthy that colocalization IHC assays
indicated that 97% of SF1 neurons express SIRT1 in controls
(Figure 1, upper panel). Conversely, only a few SIRT1-positive
cells were detected in the VMH of Sf1-Cre; Sirt1loxP/loxP mice
(Figure S1C, lower panel). The result that some SIRT1-express-
ing cells were still retained in the VMH of mutant mice is
expected, as SF1 neurons constitute a large component of but
not the entire VMH (Dhillon et al., 2006). Also, in Sf1-Cre;
Sirt1loxP/loxP mice the distribution of SIRT1-expressing cells
was unchanged in VMH’s neighboring nuclei, as for example
the ARHand the dorsomedial hypothalamic nucleus (Figure S1C,
lower panel). Importantly, colocalization IHC assays indicated
that only 9% of SF1 neurons express SIRT1 in mutants (Fig-
ure 1, lower panel).
Because SIRT1 exerts neuroprotective actions (Donmez et al.,
2010; Kim et al., 2007a; Qin et al., 2006), we explored whether
SIRT1 deficiency affects the survival of SF1 neurons. Results
shown in Figures S1B and S1D indicate that the amounts and
anatomical distribution of Sf1mRNA are normal in the hypothal-
amus of mutants. Also, no genotype differences in hypothalamic
amounts of apoptotic or neurodegenerative markers were
observed (Figures S1B, S1E, and S1F). Collectively, these results
demonstrate that Sf1-Cre; Sirt1loxP/loxP mice lack SIRT1 specifi-
cally in SF1 neurons and that this mutation does not cause death
or degeneration of SF1 neurons.
Lack of SIRT1 in SF1 Neurons Causes Hypersensitivity
to Dietary Obesity
Sf1-Cre; Sirt1loxP/loxP mice were born at the expected Mendelian
ratio, developed into adulthood similarly to their littermate
controls, and displayed normal bodyweightswhen fed ad libitum
on a standard chow (SC) diet (Figures 2A and 2B). Body fat and
lean mass were assessed by magnetic resonance imaging (MRI)
and found to be unchanged in SC-fed mutants (data not shown).
Because body length was also normal (Table S1), our results
indicate that SIRT1 in SF1 neurons is dispensable for normal
body weight in the context of normocaloric diet feeding.
Conversely, when fed on an HC diet, Sf1-Cre; Sirt1loxP/loxP mice
displayed increased propensity to develop obesity (Figures
2A and 2B). MRI and microcomputed tomography imaging anal-
yses indicated that the increased body weight is solely due to
increased fat mass (Figures 2C and 2D). In line with increasedr Inc.
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Figure 1. Deletion of SIRT1 Is Restricted to SF1
Neurons
Representative photomicrographs of brain slices from
Sirt1loxP/loxP; Z/EG (control) or Sf1-Cre; Sirt1loxP/loxP; Z/EG
mice, stained for SIRT1 and GFP. The Z/EG allele was
introduced to allow the expression of GFP selectively in
SF1 neurons, as previously described (Dhillon et al., 2006).
Dark brown staining and green fluorescence represent
SIRT1 and GFP immunoreactivity, respectively. Higher
magnification of the boxed region is in the top right corner
of the photomicrograph. Note that while almost all SF1
neurons express SIRT1 in control brains (530 out of 546
SF1 neurons were found to be SIRT1-positive), very few
express SIRT1 in Sf1-Cre; Sirt1loxP/loxP; Z/EG mice (52 out
of 576 SF1 neurons were found to be SIRT1-positive).
Abbreviations: third ventricle (3V); hypothalamic arcuate
(ARH) and ventromedial (VMH) nuclei; immunohisto-
chemistry (IHC). Dashed lines indicate VMH boundaries.
See also Figure S1.
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Metabolic Actions of SIRT1 in SF1 Neuronsadiposity, circulating levels of the adipocyte-secreted hormone
leptin were also elevated (Figure 2E). Energy imbalance was
not secondary to changes in circulating sex and/or thyroid
hormones, corticosterone levels (Table S1), altered expression
of Sf1, and/or key hypothalamic neuropeptides known to regu-
late energy balance (Figure S1B). Serum nonesterified fatty acids
were also unchanged (Table S1). Collectively, these results
demonstrate that SIRT1 in SF1 neurons is a key molecular
component of defense mechanisms against dietary obesity in
both male and female mice.0
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Cell Metabolism 14, 301Body weight is kept normal when energy
intake equals energy expenditure over time
(Vianna and Coppari, 2011). Autonomic (e.g.,
increased energy expenditure) and behavioral(e.g., reduced food intake) changes are critical defense maneu-
vers against excessive body weight gain brought on by HC diet
feeding (Dhillon et al., 2006; Ramadori et al., 2010). Thus, to
identify the defective mechanisms underpinning the hypersen-
sitivity to dietary obesity observed in mice lacking SIRT1 in SF1
neurons, the autonomic and behavioral adaptations to hyper-
caloric feeding were assessed. Energy expenditure and food
intake during the 4 days before and after the switch from SC to
HC diet were similar between groups (Figures S2A and S2B).
However, after 8 weeks on the HC diet O2 consumption, CO2n 
loxP/loxP
# 
les
Figure 2. SIRT1 in SF1 Neurons Is Required
for Normal Defenses against Diet-Induced
Obesity in Male and Female Mice
(A–E) (A) Body weight curves of standard chow
(SC)-fed Sirt1loxP/loxP (n = 21) and Sf1-Cre;
Sirt1loxP/loxP (n = 21) males, high-calorie (HC)-fed
Sirt1loxP/loxP (n = 16) and Sf1-Cre; Sirt1loxP/loxP
(n = 24) males, (B) SC-fed Sirt1loxP/loxP (n = 16) and
Sf1-Cre; Sirt1loxP/loxP (n = 13) females, HC-fed
Sirt1loxP/loxP (n = 14) and Sf1-Cre; Sirt1loxP/loxP
(n = 14) females. (C) Body composition, (D)
representative microcomputed tomography
images, and (E) serum leptin levels of Sirt1loxP/loxP
and Sf1-Cre; Sirt1loxP/loxP mice. Data shown in (C),
(D), and (E) were gathered from 28-week-old
females and 48-week-old males (n = 13–17). In (D),
red and yellow/green colors represent lean and fat
mass, respectively; females are shown. Error bars
represent SEM. Statistical analyses were done
using two-tailed unpaired Student’s t test. *p <
0.05; **p < 0.01; #p = 0.05. See also Table S1.
–312, September 7, 2011 ª2011 Elsevier Inc. 303
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Figure 3. Normophagia, Reduced Energy Expenditure, and Leptin Resistance in Mice Lacking SIRT1 in SF1 Neurons
(A–D) (A) O2 consumption, CO2 and heat production, respiratory quotient (RQ), (B) ambulatory movements, and (C) food intake were measured before body
weight diverged in 16-week-old Sirt1loxP/loxP and Sf1-Cre; Sirt1loxP/loxP females fed on a high-calorie (HC) diet for 8 weeks (n = 12). Data were collected using the
Columbus Instruments Comprehensive Lab Animal Monitoring System (CLAMS). Time 0 represents the beginning of the dark cycle in a 12 hr dark/light cycle
environment. Black and white boxes represent dark and light cycles, respectively. (D) Food intake and body weight difference following 2 days of intraperitoneal
injections of leptin (daily dose = 3 mg of leptin/kg) or saline in 16-week-old Sirt1loxP/loxP and Sf1-Cre; Sirt1loxP/loxP HC-fed females (n = 6). Error bars represent
SEM. Statistical analyses were done using two-tailed unpaired Student’s t test and one-way ANOVA (Tukey’s post test). *p < 0.05, **p < 0.01, ***p < 0.01. See also
Figure S2.
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Metabolic Actions of SIRT1 in SF1 Neuronsproduction, and ambulatory movements were all diminished
(while food intake was still normal) in Sf1-Cre; Sirt1loxP/loxP mice
(Figures 3A–3C and S2C). At the time the aforementioned meta-
bolic parameters were assessed, there were no genotype differ-
ences in body weight, fat mass, and leptinemia (Sirt1loxP/loxP and
Sf1-Cre; Sirt1loxP/loxP mice, mean values ± SEM, n = 12 each
group; body weight [g]: 23.07 ± 0.84 and 23.90 ± 1.06 [n.s.]; fat
mass [g]: 5.57 ± 0.57 and 6.48 ± 0.84 (n.s.); serum leptin
[ng/ml]: 14.39 ± 2.14 and 15.55 ± 2.28 [n.s.]; n.s. = not statistically
significant), thus ruling out the possibility that the hypometabolic
rate seen inmutants is secondary to obesity. In fact, these results
indicate that reduced energy expenditure underlies the hyper-
sensitivity to dietary obesity caused by lack of SIRT1 in SF1
neurons. Altered metabolic homeostasis was not accompanied
by changes in carbohydrate versus lipid oxidation rates, as the
respiratory quotient was normal in mutants (Figure 3A).
Because leptin’s action on SF1 neurons is required for appro-
priate body weight balance (Dhillon et al., 2006), we tested the304 Cell Metabolism 14, 301–312, September 7, 2011 ª2011 Elsevieintegrity of leptin sensitivity and found that the anorectic and
body-weight-suppressing effects of the hormone were blunted
in Sf1-Cre; Sirt1loxP/loxP mice (Figure 3D). These results suggest
that SIRT1 deletion in SF1 neurons causes leptin resistance,
a defect that, in part, may underlie the energy imbalance.
Together, our data demonstrate that lack of SIRT1 in SF1
neurons significantly predisposes to dietary obesity owing to
reduced energy expenditure.
SIRT1 in SF1 Neurons Regulates Skeletal Muscle
Insulin Sensitivity
It has been suggested that SF1 neurons coordinate glucose
metabolism (Minokoshi et al., 1999; Shiuchi et al., 2009; Tong
et al., 2007). Thus, we set out to determine the direct contribution
of SIRT1 in SF1 neurons on glucose/insulin homeostasis in
the context of either normo- or hypercaloric diet feeding. No
obvious aberrations in glycemia, insulinemia, glucose tolerance,
or insulin sensitivity were noted in SC-fed mutants (data notr Inc.
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Figure 4. Loss of SIRT1 in SF1 Neurons Causes Impaired Glucose/Insulin Homeostasis in a Body-Adiposity-Independent Manner
(A) Serum insulin level after 3 hr of food removal (fed values) or 14 hr of fasting (fasted values), glucose tolerance test (GTT), and insulin tolerance test (ITT) in
28-week-old Sirt1loxP/loxP (n = 12) and Sf1-Cre; Sirt1loxP/loxP (n = 17) males fed on a high-calorie (HC) diet.
(B) Glycemia after 3 hr of food removal (fed values) or 14 hr of fasting (fasted values), GTT, and ITT in 48-week-old Sirt1loxP/loxP (n = 34) and Sf1-Cre; Sirt1loxP/loxP
(n = 38) males fed on a HC diet. HC-fed mice were fed on a SC diet up to 8 weeks of age and then switched and maintained on a HC diet.
(C) Correlation between glycemia and fatmass or bodyweight. GTT: dose of glucose injected intraperitoneally/mouseweight = 1 g/kg. ITT: dose of insulin injected
intraperitoneally/mouse weight = 1.25 U/kg and 0.75 U/kg in males and females, respectively. Error bars represent SEM. Statistical analyses were done using
two-tailed unpaired Student’s t test. Correlation analyseswere performed by using the Spearman rank-correlation test. *p < 0.05, ***p < 0.001. See also Figure S3.
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Metabolic Actions of SIRT1 in SF1 Neuronsshown). On the other hand, when challenged with an HC diet,
mutants displayed increased susceptibility to developing
T2DM. Indeed, as shown in Figures 4A and S3A, HC-fedmutants
were hyperinsulinemic, glucose intolerant, and insulin resistant
even before their body weight, fat mass, and circulating leptin
levels diverged from HC-fed controls (Figures S3B and S3C).
Sf1-Cre; Sirt1loxP/loxP HC-fed mice also developed hypergly-
cemia (Figures 4B and S3D). Although the onset of hypergly-
cemia coincided with the onset of obesity, the former is likely
not a consequence of the latter, because no significant correla-
tions between glycemia and body weight or fat mass of Sf1-Cre;
Sirt1loxP/loxP HC-fed mice were noted (Figures 4C and S3D).
To gather insights into the mechanisms underlying the
altered glucose/insulin homeostasis, hyperinsulinemic/euglyce-
mic clamp studies were performed. As expected, in basal condi-
tions, circulating insulin and glucose levels were elevated in
Sf1-Cre; Sirt1loxP/loxP compared to Sirt1loxP/loxP HC-fed mice
(Figures 5A and 5B). During the clamp, serum insulin levels
were experimentally increased andmaintained similarly between
groups (Figure 5B). In agreement with the aforementioned data
pinpointing insulin resistance, the glucose infusion rate (GIR)
needed to clamp euglycemia (Figures 5A and 5C) was greatly
reduced in Sf1-Cre; Sirt1loxP/loxP HC-fed mice compared toCell Mecontrols (Figure 5D). Basal hepatic glucose production (HGP)
and glucose disposal rate (GDR) were not different between
groups (Figures 5E and 5F). During the clamp, insulin sup-
pressed HGP to a similar extent in both groups (Figure 5E),
a result that suggested insulin resistance in extrahepatic
tissue(s). Strikingly, insulin-induced GDR was significantly
hampered in Sf1-Cre; Sirt1loxP/loxP HC-fed mice (Figure 5F).
Because insulin-induced glucose disposal is mainly accounted
for by glucose uptake in skeletal muscle and adipose tissue,
the amounts of exogenously administered radiolabeled glucose
in these tissues were measured at completion of the clamp
experiment. As shown in Figure 5G, insulin-stimulated glucose
uptake was normal in adipose tissue but significantly reduced
in the gastrocnemius of Sf1-Cre; Sirt1loxP/loxP HC-fed mice.
Next, to independently assess in vivo insulin sensitivity,
biochemical approaches were employed. Phosphorylation of
AKT and glycogen synthase kinase 3 (GSK3, a target of
AKT) are well established events following insulin-induced acti-
vation of the PI3K signaling cascade (Manning and Cantley,
2007). Thus, the statuses of phosphorylated AKT (p-AKT) and
GSK3 (p-GSK3) have been widely used as measures of the
ability of insulin to activate its receptor. Insulin administration
greatly elevated p-AKT/AKT and p-GSK3/GSK3 ratios in liver,tabolism 14, 301–312, September 7, 2011 ª2011 Elsevier Inc. 305
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Figure 5. Loss of SIRT1 in SF1 Neurons Causes Insulin Resistance in Skeletal Muscle
(A–G) Euglycemic-hyperinsulinemic clamps were performed in Sirt1loxP/loxP (n = 9) and Sf1-Cre; Sirt1loxP/loxP (n = 8) 28-week-old conscious males that had been
fed on a high-calorie (HC) diet for 20 weeks.Mice were surgically implantedwith a right jugular vein catheter 5–7 days prior to study. Mice were fasted for 4 hr, and
blood samples were obtained from the tail vein. Two weeks prior to the clamp assay, body weight was undistinguishable between mutants and controls. At the
time clamps were performed, Sf1-Cre; Sirt1loxP/loxP mice displayed a slight increase in body weight compared to controls (p = 0.04). (A) Basal and clamp glycemia
and (B) serum insulin levels. (C) Glycemia and (D) glucose infusion rate during the clamp. (E) Basal and clamp hepatic glucose production and (F) glucose disposal
rate. (G) Tissue-specific insulin-stimulated glucose uptake. (H) Immunoblot and quantification of Akt (Thr308) and GSK-3b (Ser9) phosphorylation status relative to
total AKT (tAKT) or total GSK-3b (tGSK-3b) in gastrocnemius muscle and liver 20 min after an intraperitoneal bolus of insulin (3 U/kg) or saline in Sirt1loxP/loxP and
Sf1-Cre; Sirt1loxP/loxP standard chow (SC)-fed 28-week-old males (n = 5–6 per group). Error bars represent SEM. Statistical analyses were done using two-tailed
unpaired Student’s t test and one-way ANOVA (Tukey’s post test). *p < 0.05; **p < 0.01; ***p < 0.001. In (H), p values are saline- versus insulin-treated mice of the
same genotype, unless otherwise indicated. See also Figure S4.
Cell Metabolism
Metabolic Actions of SIRT1 in SF1 Neuronsgastrocnemius, and soleus of Sirt1loxP/loxP controls (Figures 5H
and S4). Interestingly, p-AKT/AKT and p-GSK3/GSK3 ratios
were higher in the liver (possibly a compensatory mechanism
to maintain normoglycemia) but significantly reduced in the gas-
trocnemius and soleus of insulin-injected Sf1-Cre; Sirt1loxP/loxP
mice compared to controls (Figures 5H and S4). It is noteworthy
that the blunted ability of insulin to activate PI3K-AKT signaling
in skeletal muscle is body-weight- and HC-diet-independent,
as this defect was manifest in SC-fed mutants that had normal
body weight (Figures 2A, 5H, and S4). Importantly, SF1-
neuron-specific SIRT1 overexpression led to enhanced skeletal
muscle insulin sensitivity (see below). Collectively, our results306 Cell Metabolism 14, 301–312, September 7, 2011 ª2011 Elseviedemonstrate that SIRT1 in SF1 neurons regulates insulin sensi-
tivity in skeletal muscle and that this circuitry protects against
dietary diabetes.
SIRT1 in SF1 Neurons Is Required for the Normal
Metabolic Actions of Orexin-A
A peculiar characteristic of mice lacking SIRT1 in SF1 neurons is
that the hypometabolic rate is more pronounced during the dark
than the light cycles (Figure 3A). Dark periods are times at which
feeding activities are highest inmice (Figure 3C). To better under-
stand the central defects underlying metabolic imbalance in
Sf1-Cre; Sirt1loxP/loxP mice, we explored whether the nocturnalr Inc.
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Figure 6. SIRT1 in SF1 Neurons Is Required for the Normal Metabolic Actions of Orexin-A
(A–E) (A) O2 consumption and food intake were measured in Sirt1
loxP/loxP (n = 12) and Sf1-Cre; Sirt1loxP/loxP (n = 12) HC-fed 17-week-old females after they were
maintained for 3 weeks in a lights-on, restricted feeding regimen. Data were collected using the Columbus Instruments Comprehensive Lab Animal Monitoring
System (CLAMS). Time 0 represents 6 hr after the beginning of the light cycle in a 12 hr dark/light cycle environment. HC-fed mice were fed on a SC diet up to
8 weeks of age and then switched and maintained on a HC diet. (B) Body weight and (C) daily average of food intake of Sirt1loxP/loxP and Sf1-Cre; Sirt1loxP/loxP 20-
week-old HC-fed males 12 days into icv delivery of either placebo (n = 7–8 each genotype; dashed lines) or orexin-A (n = 7 each genotype; solid lines). (D)
Glycemia and (E) serum insulin were assessed before and after 12 days of treatment. In (D) and (E), dashed lines represent average glycemia and serum insulin
levels in age-matched standard diet (SD)-fed Sirt1loxP/loxPmales, respectively. Error bars represent SEM. Statistical analyseswere done using two-tailed unpaired
Student’s t test or using one-way ANOVA (Tukey’s post test). *p < 0.05. See also Figure S6.
Cell Metabolism
Metabolic Actions of SIRT1 in SF1 Neuronshypometabolic rate is a consequence of impaired feeding-
induced energy expenditure. Interestingly, the nocturnal deficit
in O2 consumption still persisted in mutant mice that had access
to food only at lights-on times (Figure 6A), thus suggesting that
another defect(s) is present. The activity of orexin neurons
increases in wake periods, which are longest during dark cycles
in rodents (Estabrooke et al., 2001). Also, VMH-centered orexin
administration has been shown to rapidly enhance insulin sensi-
tivity in skeletal muscle (an effect the physiological relevance of
which is unknown) (Shiuchi et al., 2009). These notions prompted
us to test whether orexin’s metabolic effects are altered in
Sf1-Cre; Sirt1loxP/loxP mice. To test this hypothesis, Sf1-Cre;
Sirt1loxP/loxP and Sirt1loxP/loxP HC-fed mice were subjected to
chronic intracerebroventricular (icv) administration of orexin-A.
As shown in Figures 6B and 6C, no significant differences in
body weight and food intake were observed between Sf1-Cre;
Sirt1loxP/loxP and Sirt1loxP/loxP HC-fed mice that received either
icv orexin-A or placebo. Remarkably, icv orexin-A administration
normalized hyperglycemia and hyperinsulinemia brought on by
HC-diet feeding in controls, but failed to exert this action in
Sf1-Cre; Sirt1loxP/loxP HC-fed mice (Figures 6D and 6E). TheseCell Medata indicate that SIRT1 in SF1 neurons is required for normal
antidiabetic actions of orexin-A.
SIRT1 Overexpression in SF1 Neurons Protects against
Dietary Metabolic Imbalance
Results from the aforementioned loss-of-function mutation
experiments demonstrate that SIRT1 in SF1 neurons is required
for normal adaptive mechanisms against dietary obesity and
diabetes. To directly test whether an SF1-neuron-specific
SIRT1 gain-of-function mutation is sufficient to protect against
diet-induced metabolic imbalance, we engineered and analyzed
mice overexpressing SIRT1 only in SF1 neurons. These mutants
were generated by crossing the Sf1-Cre transgene to the
ColA1flox-STOP-Sirt1 allele that has been created by insertion of a
loxP-flanked-STOP Sirt1 coding sequence cassette into the 30
end of the ColA1 locus (Firestein et al., 2008). ColA1flox-STOP-Sirt1
mice do not overexpress SIRT1 unless Cre-recombinase is
present (Oberdoerffer et al., 2008). Accordingly, in Sf1-Cre;
ColA1flox-STOP-Sirt1 mice, the Cre-recombined ColA1flox-STOP-Sirt1
allele was detected only in sites known to express SF1, as
for example the VMH but not the ARH (Figure S5A). SIRT1tabolism 14, 301–312, September 7, 2011 ª2011 Elsevier Inc. 307
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Figure 7. SIRT1 Overexpression in SF1 Neurons Protects against Diet-Induced Obesity and Glucose/Insulin Imbalance
(A–H) (A) SIRT1 and a-tubulin (used as loading control) protein levels were assessed by immunoblot in hypothalamus of Sf1-Cre; ColA1flox-STOP-Sirt1 mice or
controls. (B) Representative photomicrographs of brain slices from control or Sf1-Cre; ColA1flox-STOP-Sirt1 mice stained for SIRT1 (dark brown staining represents
SIRT1 immunoreactivity). (C) Body weight curves, body composition, and serum leptin level and (D) oxygen consumption of high-calorie (HC)-fed Sf1-Cre;
ColA1flox-STOP-Sirt1 males (n = 12) and controls (n = 25). Body composition and serum leptin contents were measured in 48-week-old mice. (E) Food intake
and body weight difference following 2 days of intraperitoneal injections of leptin (daily dose = 3 mg of leptin/kg) or saline in 52-week-old HC-fed Sf1-Cre;
ColA1flox-STOP-Sirt1 and control males (n = 5). (F) Serum insulin level after 3 hr of food removal, (G) insulin tolerance test (ITT) in 48-week-old HC-fed Sf1-Cre;
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Cell Metabolism
Metabolic Actions of SIRT1 in SF1 Neuronsoverexpression in SF1-expressing peripheral tissues was
inconsequential, as fertility capacity, gonadal weight, basal
circadian fluctuations, and stress-induced levels of serum
corticosterone were normal in Sf1-Cre; ColA1flox-STOP-Sirt1 mice
(Table S1 and data not shown). To assess if the Cre-recombined
ColA1flox-STOP-Sirt1 allele resulted in increased SIRT1, the amount
of SIRT1 was measured and found to be 2-fold higher in
the mediobasal hypothalamus (but unchanged in other brain
areas) of Sf1-Cre; ColA1flox-STOP-Sirt1 mice compared to
controls (Figure 7A and data not shown). Importantly, SIRT1
expression was selectively increased in the VMH of Sf1-Cre;
ColA1flox-STOP-Sirt1 mice (Figure 7B), thus suggesting that these
mice have augmented SIRT1 content in SF1 neurons.
As opposed to the consequence of loss of SIRT1 in SF1
neurons, overexpression of SIRT1 in SF1 neurons protects
against dietary obesity, as HC-fed Sf1-Cre; ColA1flox-STOP-Sirt1
mice had reduced body weight, fat mass, and serum leptin levels
compared to controls fed on the same diet (Figure 7C). The
improved energy balance was not due to reduced food intake,
but brought on by increased energy expenditure (Figures 7D
and S5B). The hypermetabolic rate was not a consequence of
changes in locomotor activity, as ambulatory movements were
normal in Sf1-Cre; ColA1flox-STOP-Sirt1 mice (Figure S5C).
However, enhanced expression of Pgc1-a and SERCA2a in skel-
etal muscle suggests that increased uncoupled respiration may
underlie, at least in part, the enhanced metabolic rate displayed
by Sf1-Cre; ColA1flox-STOP-Sirt1 mice (Figure S5D). Of note, while
SIRT1 deficiency in SF1 neurons causes leptin resistance (Fig-
ure 3D), SIRT1 overexpression in SF1 neurons leads to hyper-
sensitivity to the hormone. In fact, leptin’s ability to suppress
body weight and food intake was enhanced in HC-fed Sf1-Cre;
ColA1flox-STOP-Sirt1 mice compared to controls (Figure 7E).
SF1-neuron-specific SIRT1 overexpression also led to striking
protective actions against diet-induced glucose/insulin imbal-
ance as HC-fed Sf1-Cre; ColA1flox-STOP-Sirt1 mice had reduced
circulating insulin levels, enhanced insulin sensitivity, and
glucose tolerance compared to controls (Figures 7F, 7G, and
S5E). These improvements were likely caused by enhanced skel-
etal muscle insulin sensitivity, because basal and insulin-
induced p-AKT/AKT and p-GSK3/GSK3 ratios were increased
in the gastrocnemius (but unchanged in the liver) of these
mutants (Figures 7H and S5F).
In agreement with previous findings (Dhillon et al., 2006),
body weight, food intake, glycemia, insulinemia, insulin sensi-
tivity, and glucose tolerance were all undistinguishable between
Sf1-Cre and wild-type HC-fed mice (data not shown). Therefore,
the improved and worsened metabolic profiles of Sf1-Cre;
ColA1flox-STOP-Sirt1 and Sf1-Cre; Sirt1loxP/loxP HC-fed mice,
respectively, are not the consequence of the Sf1-Cre transgene
per se. Collectively, our data demonstrate that SIRT1 overex-ColA1flox-STOP-Sirt1 (n = 12) and control mice (n = 17). ITT: dose of insulin injected in
Akt(Ser479), Akt (Thr308) and GSK-3b(Ser9) phosphorylation status relative to total
intraperitoneal bolus of insulin (5 U/kg) or saline in 14-week-old HC-fed Sf1-Cr
generated by mating Sf1-Cre and ColA1flox-STOP-Sirt1 mice. This breeding also ge
food intake, energy expenditure, glycemia, insulinemia, ITT, or GTT were noted b
pooled together and used as control. Error bars represent SEM. Statistical analys
(Tukey’s post test). *p < 0.05, **p < 0.01, ***p < 0.001. Abbreviations: third ventricle
indicate VMH boundaries. In (H), p values are saline- versus insulin-treated mice
Cell Mepression in SF1 neurons exerts robust protective actions against
diet-induced obesity and glucose/insulin imbalance, in part
owing to enhanced leptin sensitivity and improved insulin action
in skeletal muscle.
DISCUSSION
More than 1 billion people suffer from increased body weight
and/or T2DM (http://www.who.int/mediacentre/factsheets).
Both genetic/epigenetic predisposition and environmental fac-
tors contribute to this epidemic. To date, effective, long-lasting,
and safe antiobesity drugs are lacking (Vianna and Coppari,
2011). Anti-T2DM therapies are available; yet responses to these
treatments are refractory, and they do not prevent serious
morbidities (O’Rahilly et al., 2005). Thus, a better understanding
of the mechanisms protecting against obesity and T2DM is key
to the fight against these diseases. Here, we report that loss of
the protein deacetylase SIRT1 in SF1-expressing neurons
predisposes to, whereas overexpression of SIRT1 in SF1
neurons protects against, diet-induced energy and glucose/
insulin imbalance.
The overlaps between CNS pathways controlling food intake
and hedonic/mood circuitries combined with the complexity of
reducing appetite and/or enhancing energy expenditure without
adverse cardiovascular effects have been major roadblocks to
the development of effective and safe antiobesity drugs. Indeed,
the use of drugs able to curtail food intake often causes detri-
mental effects on mood and vice versa (Despre´s et al., 2005;
Di Marzo, 2008; Tardieu et al., 2003). Also, several antiobesity
drugs have been shown to have serious harmful consequences
on the cardiovascular system (Connolly et al., 1997; James
et al., 2010). In this study we report that SIRT1 in VMH SF1
neurons does not regulate food intake but instead coordinates
energy expenditure adaptations against excessive body weight
gain (Figures 2, 3, and 7). Normophagia concomitant with hypo-
metabolic rate in the context of chronic HC diet feeding is also
a consequence of SIRT1 deletion in another group of extra-
VMH neurons (i.e., POMC neurons) (Ramadori et al., 2010).
Thus, results from this (Figures 2, 3, 7, and S5) and our previous
study (Ramadori et al., 2010) indicate a divergence between the
roles of SIRT1 in SF1 and POMC neurons on food intake versus
energy expenditure. Collectively, our data suggest that harness-
ing SIRT1 function in POMC and SF1 neurons may represent an
effective approach to reducing body weight without causing
detrimental behavioral changes.
An interesting aspect of our study is that it unveils the exis-
tence of a previously unrecognized form of diabetes, which is
neurogenic T2DM. Although the onsets of hyperglycemia and
increased body weight coincided (Figures 4B and S3D), hyperin-
sulinemia, glucose intolerance, and insulin resistance were alltraperitoneally/mouse weight = 1.25 U/kg. (H) Immunoblot and quantification of
AKT (tAKT) or total GSK-3b (tGSK-3b) in gastrocnemius muscle 10 min after an
e; ColA1flox-STOP-Sirt1and control mice. Sf1-Cre; ColA1flox-STOP-Sirt1 mice were
nerated Sf1-Cre and wild-type mice. Because no differences in body weight,
etween Sf1-Cre and wild-type HC-fed mice, data from these two groups were
es were done using two-tailed unpaired Student’s t test and one-way ANOVA
(3V); hypothalamic arcuate (ARH) and ventromedial (VMH) nuclei. Dashed lines
of the same genotype, unless otherwise indicated. See also Figure S5.
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and adiposity differed from controls (Figures 4A, S3A, S3B,
and S3C). Therefore, glucose/insulin imbalance likely is a primary
defect caused by lack of SIRT1 in SF1 neurons and not
secondary to obesity. This contention is further bolstered by
the following observations: (i) the impaired insulin sensitivity in
skeletal muscle was detected in SC-fed mutant mice, the body
weight and adiposity of which were not different from controls
(Figures 2, 5H and S4); (ii) the insulinemia- and glycemia-
lowering actions of icv orexin-A administration were blunted in
mice lacking SIRT1 in SF1 neurons, although their body weights
were not different from controls (Figures 6B, 6D and 6E); (iii) there
were no correlations between glycemia and body weight or
fat mass in diabetic and obese Sf1-Cre; Sirt1loxP/loxP HC-fed
mice (Figures 4B, 4C, and S3D), and (iv) increased adiposity
does not always lead to glucose/insulin imbalance (Kim et al.,
2007b). Indeed, HC-fed mice lacking SIRT1 in POMC neurons
display normal glucose/insulin homeostasis, despite the fact
that they have a similar degree of obesity to the one seen in
HC-fed Sf1-Cre; Sirt1loxP/loxP mice (Ramadori et al., 2010).
Our results suggest that SIRT1 in SF1 neurons directly controls
skeletal muscle insulin sensitivity, as SIRT1 deletion in SF1
neurons impairs, whereas SIRT1 overexpression in SF1 neurons
enhances, insulin action selectively in skeletal muscle (Figures
5H, 7H, and S4). Changes in neuroendocrine circulating factor
levels and/or the activity of the autonomic nervous system may
underlie this regulation. We favor the latter possibility, because
data shown in Figure 6 indicate that orexin-A’s antidiabetic
actions are severely impaired in mutant mice, and it has been
shown that VMH-centered orexin-A delivery enhances insulin
sensitivity in skeletal muscle via increased sympathetic tone in
this tissue (Shiuchi et al., 2009). Future studies are required to
establish the underpinnings of the SIRT1-in-SF1-neuron-to-
skeletal-muscle circuitry. Regardless of the mechanisms, our
loss- and gain-of-function studies unveiled SIRT1 in SF1 neurons
as a critical molecule of homeostatic pathways safeguarding
glucose/insulin homeostasis, and as such SIRT1 in SF1 neurons
may represent an ideal target of antidiabetic drugs.
Orexin-A signaling is impaired in mice lacking SIRT1 in SF1
neurons (Figure 6). There are at least three possibilities that are
not mutually exclusive that could explain this defect. Orexin-A
has been shown to affect the biophysical properties of VMH
SF1 neurons (Shiuchi et al., 2009). Thus, one possible explana-
tion is that the direct effects of this neuropeptide on membrane
potential and firing rate of mutant SF1 neurons are altered. To
test this idea, we employed hypothalamic slice preparations
and measured electrophysiological properties of SF1 neurons
containing or devoid of SIRT1. As shown in Figure S6A, we found
that SF1 neurons are heterogeneous in respect to their biophys-
ical responsiveness to orexin-A as 33% or 55% of SF1
neurons displayed excitatory or inhibitory outcomes to the
neuropeptide, respectively. A similar percentage of SF1 neurons
lacking SIRT1 was either activated or inhibited by orexin-A (Fig-
ure S6B). Membrane potential and firing rates at basal and after
orexin-A administration were also similar between SF1 neurons
containing or devoid of SIRT1 (Figures S6A and S6B). Thus,
imperfections in other pathways downstream of orexin receptor
signaling in SF1 and/or non-SF1 neurons may underlie the
diminished orexin-A’s antidiabetic actions observed in Sf1-Cre;310 Cell Metabolism 14, 301–312, September 7, 2011 ª2011 ElsevieSirt1loxP/loxP mice. Largely due to the lack of reliable readouts
for orexin receptor intracellular signaling and the widespread
CNS distribution of orexin neuron projections (Chemelli et al.,
1999), these two possibilities could not be resolved in this study.
Interestingly, deletion of SIRT1 in SF1 neurons leads to re-
duced, whereas overexpression of SIRT1 in SF1 neurons causes
increased, sensitivity to leptin’s antiobesity actions (Figures 3E
and 7E). Furthermore, deletion of SIRT1 in SF1 neurons causes
insulin resistance in the skeletal muscle, while overexpression
has the opposite effect (Figures 5H and 7H). These results
suggest that the metabolic phenotypes engendered by either
loss or overexpression of SIRT1 in SF1 neurons are caused by
changes in similar pathways. However, while locomotor activity
was reduced in Sf1-Cre; Sirt1loxP/loxP mice, this parameter was
unchanged in Sf1-Cre; ColA1flox-STOP-Sirt1 mutants (Figures 3B
and S5C). Also, expression of SERCA2a in skeletal muscle was
increased in Sf1-Cre; ColA1flox-STOP-Sirt1 but unchanged in Sf1-
Cre; Sirt1loxP/loxP mice (Figure S5D and data not shown). There-
fore, our data also indicate that mechanisms affected by the
loss-of-function are unaltered by the gain-of-function mutation
and vice versa.
Putative SIRT1-activating compounds (STACs) have been
shown to exert beneficial actions against metabolic imbalance
in animal models of obesity and T2DM (Baur et al., 2006;
Lagouge et al., 2006; Milne et al., 2007; Ramadori et al., 2009).
Genetically induced SIRT1 overexpression has also been shown
to improve metabolic defects in similar animal models (Banks
et al., 2008; Pfluger et al., 2008). However, due to uncertainties
regarding STAC specificity (Beher et al., 2009; Pacholec et al.,
2010) and the ubiquitous nature of SIRT1 gain-of-function ex-
periments (Banks et al., 2008; Pfluger et al., 2008), the relevance
of SIRT1 in mediating STAC actions and in which cell-type
enhanced SIRT1 would eventually lead to improved metabolic
imbalance have not been established yet. The current model,
however, is that enhanced SIRT1 activity in peripheral sites
(e.g., skeletal muscle and adipose tissue) is a mechanistic
link between STAC administration and improved metabolism
(Banks et al., 2008; Baur et al., 2006; Lagouge et al., 2006;
Milne et al., 2007). Interestingly, based on our results that
SF1-neuron-specific SIRT1 gain-of-function mutation protects
against diet-induced metabolic defects (Figures 7 and S5) this
paradigm will need to be amended to include SIRT1 in SF1
neurons as a novel molecular target for antiobesity and anti-
T2DM compounds.
In summary, the present study has uncovered critical protec-
tive roles for SIRT1 in VMH SF1 neurons against dietary obesity
and diabetes. These results represent an important step forward
in our understanding of the mechanisms safeguarding metabolic
homeostasis.EXPERIMENTAL PROCEDURES
Generation of Sf1-Cre; Sirt1loxP/loxP and Sf1-Cre; ColA1flox-STOP-Sirt1
Mice
Micewere housed in groups of four to five with food, either an SC rodent diet or
the HC diet (D12331 from Research Diets, New Brunswick, NJ), and water
available ad libitum in light- and temperature-controlled environments, unless
otherwise specified. Care of mice was within the Institutional Animal Care and
Use Committee (IACUC) guidelines, and all the procedures were approved by
the University of Texas Southwestern Medical Center IACUC. HC-fed micer Inc.
Cell Metabolism
Metabolic Actions of SIRT1 in SF1 Neuronswere fed on a SC diet up to 8 weeks of age and then switched and maintained
on a HC diet.
Immunohistochemistry and In Situ Hybridization Histochemistry
Analyses
SIRT1 immunohistochemistry was performed on brain sections from mice
using SIRT1-specific antibodies as previously described (Ramadori et al.,
2010).
Body Composition, Oxygen Consumption, and Locomotor Activity
Analyses
Body fat and lean mass were determined using the EchoMRI-100 system
(Echo Medical Systems, Houston, TX). Metabolic rate and physical activity
were measured using a comprehensive lab animal monitoring system
(Columbus Instruments, Columbus, OH).
Hyperinsulinemic-Euglycemic Clamp Study
Hyperinsulinemic-euglyclemic clamps were performed as previously
described (Hill et al., 2010).
Central Orexin Administration
A cannula was positioned stereotaxically into the cerebral lateral ventricles
(0.34 mm from bregma; ± 1 mm lateral; 2.3mm from skull) and a small
osmotic minipump (model 1004, Alzet, Cupertino, CA) implanted subcutane-
ously was attached via catheter to the cannula for icv infusion.
Electrophysiological Study
Whole-cell patch-clamp recordings were made from SF1 neurons of Sf1-Cre;
Sirt1loxP/loxP; Z/EG or Sf1-Cre; Z/EG (control) mice. During the recordings,
neurons were maintained in hypothalamic slice preparations and data analysis
was performed as previously described (Dhillon et al., 2006).
Statistical Analysis
Data sets were analyzed for statistical significance using Prism (GraphPad,
San Diego, CA) for a two-tailed unpaired Student’s t test, when two groups
were compared, or one-way ANOVA (Tukey’s post test), when three or more
groups were compared.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, one table, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.cmet.2011.06.014.
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